Literature review: indications and complications of fecal microbiota transplantation
DOI:
https://doi.org/10.33936/qkrcs.v8i2.6688Abstract
which is why Fecal Microbiota Transplantation (FMT) has become a therapeutic option over time due to the clinical results for patients. A descriptive cross-sectional Scoping Review study was carried out using the PRISMA statement, the Pubmed and Lilacs database, considering articles published in the last 5 years with the aim of offering a bibliographic review on the indications and complications of transplant treatment. of fecal microbiota, 11 studies were obtained that met the criteria, being analyzed and concluding that the mode of administration of FMT varies depending on the pathology treated, there are encouraging results on the use of Microbiota Transplantation Fecal in patients with Ulcerative Colitis, Crohn’s Disease and Recurrent Clostridium Difficile Infection as well as extraintestinal processes Diabetes Mellitus, Obesity and Metabolic Syndrome. However, its complications include the transmission of enteric pathogens, infection and/or sepsis, so more research is needed to fully understand its long-term effects.
Downloads
References
Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther [Internet]. el 1 de diciembre de 2022 [citado el 16 de enero de 2024];7(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/35461318/
da Luz MRMP, Waizbort RF. Transplantes de microbiota fecal para tratamento da colite pseudomembranosa (1958-2013): prioridade de descoberta e estilos de pensamento na literatura acadêmica. Hist ciênc saúde-Manguinhos [Internet]. el 1 de julio de 2020 [citado el 16 de enero de 2024];27(3):859–78. Disponible en: https://pesquisa.bvsalud.org/portal/resource/es/biblio-1134074
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms [Internet]. el 1 de enero de 2019 [citado el 16 de enero de 2024];7(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/30634578/
Fuxman C, Sicilia B, Linares ME, García-López S, González Sueyro R, González-Lamac Y, et al. GADECCU 2022 Guideline for the treatment of Ulcerative Colitis. Adaptation and updating of the GETECCU 2020 Guideline. Gastroenterol Hepatol. el 1 de marzo de 2023;46:S1–56.
An J, Liu Y, Wang Y, Fan R, Hu X, Zhang F, et al. The Role of Intestinal Mucosal Barrier in Autoimmune Disease: A Potential Target. Front Immunol [Internet]. el 1 de julio de 2022 [citado el 16 de enero de 2024];13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35844539/
Lai S, Yan Y, Pu Y, Lin S, Qiu JG, Jiang BH, et al. Enterotypes of the human gut mycobiome. Microbiome [Internet]. el 1 de diciembre de 2023 [citado el 10 de enero de 2024];11(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/37563687/
Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut [Internet]. el 1 de diciembre de 2020 [citado el 10 de enero de 2024];69(12):2232–43. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32917747/
National Center for Biotechnology Information [Internet]. [citado el 1 de octubre de 2024]. Disponible en: https://www.ncbi.nlm.nih.gov/
LILACS, un espacio de todos y para todos – Boletín BIREME/OPS/OMS [Internet]. [citado el 10 de enero de 2024]. Disponible en: https://boletin.bireme.org/2020/11/02/lilacs-un-espacio-de-todos-y-para-todos/
Ianiro G, Bibbò S, Porcari S, Settanni CR, Giambò F, Curta AR, et al. Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes [Internet]. 2021 [citado el 4 de mayo de 2024];13(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/34709989/
Wilson BC, Vatanen T, Jayasinghe TN, Leong KSW, Derraik JGB, Albert BB, et al. Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. Microbiome. el 1 de diciembre de 2021;9(1).
De Groot P, Nikolic T, Pellegrini S, Sordi V, Imangaliyev S, Rampanelli E, et al. Original research: Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut [Internet]. el 1 de enero de 2021 [citado el 4 de mayo de 2024];70(1):92. Disponible en: /pmc/articles/PMC7788262/
Zecheng L, Donghai L, Runchuan G, Yuan Q, Qi J, Yijia Z, et al. Fecal microbiota transplantation in obesity metabolism: A meta analysis and systematic review. Diabetes Res Clin Pract [Internet]. el 1 de agosto de 2023 [citado el 4 de mayo de 2024];202. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37356723/
Pipek B, Valentová H, Fojtík P, Urban O. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience. Casopis Lekaru Ceskych. 2022 ;161(3-4):126-130. PMID: 36100450.
Kachlíková M, Sabaka P, Koščálová A, Bendžala M, Dovalová Z, Stankovič I. Comorbid status and the faecal microbial transplantation failure in treatment of recurrent Clostridioides difficile infection - pilot prospective observational cohort study. BMC Infect Dis [Internet]. el 16 de enero de 2020 [citado el 4 de mayo de 2024];20(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/31948404/
Terveer EM, Vendrik KEW, Ooijevaar RE, Lingen E van, Boeije-Koppenol E, Nood E van, et al. Faecal microbiota transplantation for Clostridioides difficile infection: Four years’ experience of the Netherlands Donor Feces Bank. United European Gastroenterol J [Internet]. el 1 de diciembre de 2020 [citado el 8 de mayo de 2024];8(10):1236. Disponible en: /pmc/articles/PMC7724536/
Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Hurtado J, Carrellas M, et al. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection. Inflamm Bowel Dis [Internet]. el 1 de septiembre de 2021 [citado el 8 de mayo de 2024];27(9):1371. Disponible en: /pmc/articles/PMC8376126/
Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database of Systematic Reviews. el 25 de abril de 2023;2023(4).
Jamshidi P, Farsi Y, Nariman Z, Hatamnejad MR, Mohammadzadeh B, Akbarialiabad H, et al. Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Mol Sci [Internet]. el 1 de octubre de 2023 [citado el 8 de mayo de 2024];24(19). Disponible en: https://pubmed.ncbi.nlm.nih.gov/37834010/
Halsey TM, Thomas AS, Hayase T, Ma W, Abu-Sbeih H, Sun B, et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med [Internet]. el 14 de junio de 2023 [citado el 8 de mayo de 2024];15(700). Disponible en: https://pubmed.ncbi.nlm.nih.gov/37315113/
Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, et al. Fecal Microbiota Transplantation in Neurological Disorders. Front Cell Infect Microbiol [Internet]. el 24 de marzo de 2020 [citado el 8 de mayo de 2024];10. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32266160/
Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol [Internet]. el 1 de julio de 2020 [citado el 8 de mayo de 2024];115(7):1055–65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32618656/
Al KF, Craven LJ, Gibbons S, Parvathy SN, Wing AC, Graf C, et al. Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial. Mult Scler J Exp Transl Clin [Internet]. el 1 de abril de 2022 [citado el 8 de mayo de 2024];8(2). Disponible en: /pmc/articles/PMC9102167/
Zecheng L, Donghai L, Runchuan G, Yuan Q, Qi J, Yijia Z, et al. Fecal microbiota transplantation in obesity metabolism: A meta analysis and systematic review. Diabetes Res Clin Pract [Internet]. el 1 de agosto de 2023 [citado el 8 de mayo de 2024];202. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37356723/
Aràjol C, Aira Gómez A, González-Suárez B, Casals-Pascual C, Martí Martí S, Domínguez Luzón MÁ, et al. Donor selection for faecal microbiota transplantation. Consensus document of the Catalan Society of Gastroenterology and the Catalan Society of Infectious Diseases and Clinical Microbiology. Gastroenterol Hepatol [Internet]. el 1 de febrero de 2021 [citado el 17 de enero de 2024];44(2):175–80. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33309073/
Fernández MF, Mangano A. Una mirada a nuestra vida interior: el microbioma intestinal. Med infant [Internet]. 2023 [citado el 16 de enero de 2024];83–4. Disponible en: https://www.medicinainfantil.org.ar/images/stories/volumen/2023/xxx_1_083.pdf
Published
Issue
Section
License
Copyright (c) 2025 María Cecilia Moreira Solano, Allan Akiro Naula Pacheco, Roberto Eduardo Aguirre Fernández
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
